Table 7.
Results from bio-assays using WHO cone test
| Variable | 12 months | 24 months | 36 months |
|---|---|---|---|
| N = 30 | N = 30 | N = 30 | |
| Zamfara | |||
| Knock down 60 min | |||
| Mean (95% CI) | 46.8% (39.5–54.1) | 66.1% (60.0–72.3) | 45.2% (40.9–49.6) |
| Median (IQR) | 50.0% (35.0–64.0) | 69.0% (56.0–80.0) | 43.0% (34.0–56.0) |
| Mortality 24 h | |||
| Mean (95% CI) | 64.4% (57.8–71.2) | 99.6% (99.5–100) | 98.3% (96.6–100) |
| Median (IQR) | 70.0% (60.0–80.0) | 100% (100–100) | 100% (100–100) |
| Optimal effectiveness | |||
| Estimate (95% CI) | 30.0% (16.2–48.7) | 100% (–) | 96.7% (77.7–99.6) |
| Minimal effectiveness | |||
| Estimate (95% CI) | 80.0% (63.4–90.2) | 100% (–) | 100% (–) |
| Ebonyi | |||
| Knock down 60 min | |||
| Mean (95% CI) | 58.3% (50.7–65.9) | 52.0% (46.2–57.8) | 42.3% (37.4–47.1) |
| Median (IQR) | 60.0% (34.0–80.0) | 50.0% (40.0–66.0) | 40.0% (34.0–48.0) |
| Mortality 24 h | |||
| Mean (95% CI) | 65.0% (60.3–69.7) | 99.2% (98.4–99.9) | 97.3% (95.2–99.5) |
| Median (IQR) | 64.0% (60.0–74.0) | 100% (100–100) | 100% (100–100) |
| Optimal effectiveness | |||
| Estimate (95% CI) | 16.7% (7.3–33.6) | 100% (–) | 96.7% (77.7–99.6) |
| Minimal effectiveness | |||
| Estimate (95% CI) | 90.0% (72.7–96.8) | 100% (–) | 100% (–) |
| Oyo | |||
| Knock down 60 min | |||
| Mean (95% CI) | 53.4% (47.9–58.9) | 47.5% (41.3–53.6) | n.a |
| Median (IQR) | 54.0% (42.0–66.0) | 44.0% (36.0–58.0) | |
| Mortality 24 h | |||
| Mean (95% CI) | 99.7% (99.2–100) | 98.5% (97.0–99.9) | n.a |
| Median (IQR) | 100% (100–100) | 100% (100–100) | |
| Optimal effectiveness | |||
| Estimate (95% CI) | 100% (–) | 100% (–) | n.a |
| Minimal effectiveness | |||
| Estimate (95% CI) | 100% (–) | 100% (–) | n.a |